Skip to main content
    R

    Regenxbio Inc (RGNX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.24
    -0.08 (-1.09%)

    Market Cap: $505.18M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Regenxbio Inc (RGNX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Regenxbio (RGNX) has a market cap of $505.18M and an enterprise value of $409.38M. Its share count is up 26.26% from a year earlier. It kept -113.85% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 18.96% below the market cap, as cash exceeds debt.

    Market Cap$505.18M
    Enterprise Value$409.38M
    Latest price (Nov 17, 2026)$7.24

    Key Dates

    The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 3, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 23.56% in the quarter ended Sep 30, 2026 and grew 13.34% a year over 2 years.

    Shares Outstanding65.26M
    Shares Change (YoY)+26.26%
    Shares Change (QoQ)+23.56%
    Share Count Growth (2Y CAGR)+13.34%

    Valuation Ratios

    Sales and book value multiples are 3.1x and 3.2x. Its year-end P/S ranged from 4.4x to 106.7x from 2016 to 2025.

    P/S Ratio3.1x
    Forward P/S3.2x
    P/B Ratio3.2x

    Valuation history and multiples

    Price Statistics

    The stock is down 37.10% over 52 weeks and trades 4.61% below its 50-day average.

    Beta (1Y)1.81
    52-Week Change-37.10%
    1-Month Change+1.26%
    3-Month Change-39.77%
    6-Month Change+27.92%
    5-Year Change-79.68%
    10-Year Change-54.29%
    Total Return (1Y)-37.10%
    Total Return (3Y CAGR)-28.11%
    Total Return (5Y CAGR)-25.73%
    Return vs SPY (1Y)-47.20%
    Max Drawdown (1Y)-64.64%
    Max Drawdown (3Y)-78.42%
    Sharpe Ratio (1Y)-0.45
    Correlation with SPY (1Y)0.26
    50-Day Average$7.59
    200-Day Average$8.84
    52-Week Range$5.46 to $16.19
    RSI (14 Days)45.8
    Average Volume (20 Days)1.25M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.74x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.74x
    Quick Ratio4.74x
    Debt / Equity0.00x
    Interest Coverage-4.06x

    Returns and Efficiency

    Return on equity is -118.36% over the last 12 months, against a 5-year average of -79.66%.

    Return on Equity (ROE)-118.36%
    Return on Assets (ROA)-37.60%
    Return on Capital Employed (ROCE)-36.95%
    ROE (5Y Average)-79.66%
    ROA (5Y Average)-31.92%
    Asset Turnover0.31x
    Receivables Turnover2.67x

    Scores

    RGNX has an Altman Z-Score of -2.88, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-2.88
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $153.91M over the last 12 months is down 4.59% from the 12 months before.

    Revenue$153.91M
    Revenue Growth (YoY)-4.59%
    Gross Profit$153.91M
    Operating Income-$147.27M
    Pretax Income-$175.23M
    Net Income-$175.23M
    EBITDA-$135.12M
    EBIT-$147.20M
    Reported EPS (TTM)-$3.21

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 31.77% of the $466.04M in total assets.

    Cash and Equivalents$95.80M
    Total Debt$0
    Net Cash$95.80M
    Net Cash Per Share$1.47
    Working Capital$253.21M
    Shareholder Equity$148.04M
    Book Value Per Share$2.27
    Total Assets$466.04M
    Total Liabilities$318.00M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $2.70M of capital spending, operating cash flow left -$154.80M of free cash flow.

    Operating Cash Flow-$152.10M
    Capital Expenditures$2.70M
    Free Cash Flow-$154.80M
    FCF Per Share-$2.35
    Depreciation and Amortization$17.91M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -95.68%.

    Gross Margin100.00%
    Operating Margin-95.68%
    Pretax Margin-113.85%
    Net Margin-113.85%
    EBITDA Margin-87.79%
    EBIT Margin-95.64%
    FCF Margin-100.58%
    Gross Margin (5Y Average)81.18%

    Growth

    Revenue grew 14.78% a year over 3 years.

    Revenue Growth (3Y CAGR)+14.78%
    Revenue Growth (5Y CAGR)+1.97%
    Book Value Per Share Growth (2Y CAGR)-47.07%
    Tangible Book Per Share Growth (2Y CAGR)-47.07%

    Revenue and profit by year

    Dividends and Yields

    RGNX does not pay a dividend. Its free cash flow yield is -32.76%.

    FCF Yield-32.76%
    Buyback Yield-27.26%
    Shareholder Yield-27.26%

    Peer Position

    Against 4 similar companies, RGNX has the lowest P/S.

    P/S Ratio3.1x vs 6.2x median
    Revenue Growth (Trailing 4 Quarters, YoY)-4.59% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 7.76% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+7.76%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RGNX

    What is RGNX's market cap?

    Regenxbio has a market cap of $505.18M. Its enterprise value, which adds debt and subtracts cash, is $409.38M.

    How many shares of RGNX are outstanding?

    Regenxbio has 65.26M shares outstanding. The count is up 26.26% from a year earlier.

    Does RGNX pay a dividend?

    No. Regenxbio does not pay a dividend.

    How much debt does RGNX have?

    Regenxbio has $0 of total debt and $95.80M of cash and equivalents, a net cash position of $95.80M.